<i>Helicobacter pylori</i> strains and histologically‐related lesions affect the outcome of triple eradication therapy: a study from southern Italy

Russo, Francesco; Berloco, P.B.; Cuomo, Rosario; Caruso, Maria Lucia; Matteo, G. Di; Giorgio, Piero; Francesco, Vincenzo De; Leo, Alfredo Di; Ierardi, Enzo

doi:10.1046/j.1365-2036.2003.01443.x

Cited by 23 publications

(24 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therapeutic significance of gastritis topography for patients with peptic ulcer disease and non‐ulcer dyspepsia was not evident between the individual subgroups (Figure 3). Such differences have previously been described and may be related to the complex host and bacterial interactions 28, 29 . In this context, our results should be interpreted with caution because of the limited number of the included patients.…”

Section: Discussionsupporting

confidence: 44%

Rifabutin‐ and furazolidone‐based Helicobacter pylori eradication therapies after failure of standard first‐ and second‐line eradication attempts in dyspepsia patients

Qasim

Sebastian

Thornton

et al. 2004

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYBackground: Optimal management approach is not well defined for subjects who fail initial first-and second-line Helicobacter pylori eradication attempts and are dealt on a case-by-case basis by the specialists. Aim: To evaluate the efficacy and safety of standard and 'rescue' eradication therapies at primary and secondary care levels. Methods: H. pylori infected dyspepsia patients referred to our C13 urea breath testing laboratory between January 1999 to February 2002 were included. Eradication failure at secondary care level was treated using strategies including antibiotic sensitivity testing and the use of rifabutin-and furazolidone-based therapies. Results: 3280 patients received standard first-line eradication therapy, which was successful in 2530

show abstract

Section: Discussionsupporting

confidence: 44%

Rifabutin‐ and furazolidone‐based Helicobacter pylori eradication therapies after failure of standard first‐ and second‐line eradication attempts in dyspepsia patients

Qasim

Sebastian

Thornton

et al. 2004

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Therefore, this sequential schedule could significantly improve the effectiveness of treatment in comparison with current triple therapies (increase in eradication rate of 15–25%) with only a slight increase in cost (+ 4.63 euros per patient). Moreover, although the current literature reports that a smoking habit, 29 , 30 young age, 31 male sex 32 and histology 33 are predictors for H. pylori eradication failure, none appeared to affect the eradication efficacy of the sequential regimen, regardless of clarithromycin dosage.…”

Section: Discussionmentioning

confidence: 74%

Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non‐ulcer dyspepsia

Francesco

Valle

Stoppino

et al. 2004

Aliment Pharmacol Ther

Self Cite

View full text Add to dashboard Cite

SUMMARYBackground: A novel 10-day sequential treatment regimen recently achieved a significantly higher eradication rate than standard 7-day therapy in both peptic ulcer disease and non-ulcer dyspepsia. Its higher performance has recently been confirmed using a halved clarithromycin dose in peptic ulcer disease. Aims: To evaluate whether an acceptable eradication rate could also be obtained by halving the clarithromycin dose in dyspeptic patients and to assess the role of possible factors affecting the outcome of therapy. Methods: In a prospective, open-label study, 162 patients with non-ulcer dyspepsia and Helicobacter pylori infection, assessed by rapid urease test and histology, were enrolled. Patients were randomized to receive either 10-day sequential therapy, comprising rabeprazole 20 mg b.d. plus amoxicillin 1 g b.d. for the first

show abstract

“…Eighth, other virulence factors of H . pylori , such as dupA , oipA and iceA [27–30]may also affect eradication outcomes. However, relatively few of these factors have been reported in the literature, which did not allow us to conduct a systematic meta-analysis of them.…”

Section: Discussionmentioning

confidence: 99%

The association between vacA or cagA status and eradication outcome of Helicobacter pylori infection: A meta-analysis

Wang

Gong

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

BackgroundH. pylori virulence factors, especially vacA and cagA are important in gastroduodenal disease pathogenesis and affect cure rates. This meta-analysis aimed to clarify the association between vacA or cagA status and eradication outcome of H. pylori infection.MethodsA literature search was performed using electronic databases to identify studies. Twenty-six prospective studies were determined eligible. Meta-analytical techniques were conducted to calculate eradication rates and pooled relative ratios (RR).ResultsThe eradication rate was greater approximately 10% in vacA s1 compared with vacA s2 infected patients, and the pooled RR was 1.164 (95%CI: 1.040–1.303, P = 0.008). A significant association existed between vacA s1 and higher eradication rates in Europe (RR: 1.203, 95%CI: 1.003–1.442, P = 0.046) and Asia (RR: 1.187, 95%CI: 1.028–1.371, P = 0.020), in triple therapy patients (RR: 1.175, 95%CI: 1.012–1.365, P = 0.035). Eradication rates were similar for vacA m1 and m2 genotypes (RR: 0.981, 95%CI: 0.891–1.080, P = 0.690), whereas they were higher by approximately 8% in cagA-positive compared with cagA-negative infected patients, with a pooled RR of 1.094 (95%CI: 1.025–1.168, P = 0.007). A significant association existed between cagA-positive and increased eradication rates in Europe (RR: 1.138, 95%CI: 1.000–1.295, P = 0.049) and Asia (RR: 1.118, 95%CI: 1.051–1.190, P<0.001), in using PCR (RR: 1.232, 95%CI: 1.142–1.329, P<0.001) and protein chips (RR: 1.200, 95%CI: 1.060–1.359, P = 0.004), in triple therapy patients (RR: 1.090, 95%CI: 1.006–1.181, P = 0.034).ConclusionsEvidence indicates that infection with vacA s1, cagA-positive strains, but not vacA s2, cagA-negative, is more conducive to H. pylori eradication.

show abstract

Helicobacter pylori strains and histologically‐related lesions affect the outcome of triple eradication therapy: a study from southern Italy

Cited by 23 publications

References 28 publications

Rifabutin‐ and furazolidone‐based Helicobacter pylori eradication therapies after failure of standard first‐ and second‐line eradication attempts in dyspepsia patients

Rifabutin‐ and furazolidone‐based Helicobacter pylori eradication therapies after failure of standard first‐ and second‐line eradication attempts in dyspepsia patients

Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non‐ulcer dyspepsia

The association between vacA or cagA status and eradication outcome of Helicobacter pylori infection: A meta-analysis

Contact Info

Product

Resources

About